TXG vs UTHR
10x Genomics, Inc. vs United Therapeutics — AI-powered side-by-side comparison
TXG
10x Genomics, Inc.
53
Watch
VS
UTHR
United Therapeutics
72
Buy
| Metric | TXG | UTHR |
|---|
| AI Score |
53
|
72
|
| Price |
$58.48
|
$514.89
|
| P/E Ratio |
-99.12×
|
17.05×
|
| ROE |
-5.5%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
70.0%
|
86.1%
|
| Debt / Equity |
0.10×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.3
|
52.2
|
| Beta |
2.039
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for TXG versus UTHR.
UTHR leads by 19 points.
UTHR scores 72/100 (Buy) versus TXG at 53/100 (Watch).
TXG Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -4.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- RSI at 79 is in overbought territory — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.